AI-generated research brief — verify at source
Enpatoran Misses Dose-Response Target in Moderate-to-Severe SLE Despite Numerical Gains
A 24-week randomised trial found that enpatoran, an oral TLR7/8 inhibitor, did not achieve a statistically significant dose-response relationship for BICLA response rate in moderate-to-severe SLE (p=0.14), though all three doses produced numerically higher response rates than placebo (25 mg: 58%, 50 mg: 49%, 100 mg: 49% vs placebo: 39%). The absence of a clear dose-dependent pattern, with the lowest dose showing the strongest signal, leaves the optimal dosing strategy and the interpretation of the clinical benefit uncertain.
What Was Studied
This trial investigated whether enpatoran, a small-molecule oral inhibitor of Toll-like receptors 7 and 8 (TLR7/8), could improve disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) in a dose-dependent manner, as measured by BICLA response rate at 24 weeks. TLR7 and TLR8 are implicated in activating both innate and adaptive immune pathways that contribute to lupus pathogenesis, making their inhibition a mechanistically grounded therapeutic target.
How It Was Studied
This was a multicentre, international, randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (Cohort B of the WILLOW basket study), conducted across 132 centres in 22 countries. Adults aged 18–75 years with moderate-to-severe SLE, disease duration of at least 6 months, and a stable background medication regimen were eligible to participate. The trial enrolled 354 participants in two sequential parts: Part 1 randomised participants 1:2 to placebo or 100 mg enpatoran twice daily; once 60 participants were enrolled, Part 2 allocated additional participants 1:1:1:1 to 25 mg, 50 mg, 100 mg enpatoran, or placebo twice daily, all for 24 weeks. Glucocorticoid doses were mandatorily tapered from weeks 2 to 12, targeting a prednisone-equivalent of no more than 5 mg per day.
What Was Observed
- Primary endpoint not met: The trial failed to demonstrate a statistically significant dose-response relationship for BICLA response rate at week 24 (no significant trend, p=0.14). This was the defined primary objective, and its non-fulfilment is the central result of the study.
- Numerically higher response rates across all enpatoran doses: Despite missing the primary endpoint, all enpatoran groups outperformed placebo numerically. The 25 mg dose showed the highest response rate — about 2.2 times the odds of a BICLA response compared with placebo (OR 2.2, 95% CI 1.1–4.0). The 50 mg and 100 mg doses showed smaller and statistically uncertain effects (50 mg: OR 1.5, 95% CI 0.8–2.8; 100 mg: OR 1.6, 95% CI 0.9–2.8).
- Safety and tolerability: Enpatoran was generally well tolerated across all doses. The most common treatment-emergent adverse event was diarrhoea, occurring at low rates across all groups including placebo. Serious adverse events were uncommon and occurred at similarly low rates in both active and placebo groups (1–4% across all arms).
- Anomalous dose-response pattern: The 25 mg dose produced the largest observed treatment effect, while higher doses (50 mg and 100 mg) showed smaller and overlapping confidence intervals with placebo, representing a non-linear and pharmacologically unexplained pattern.
Why This Matters
This trial provides early phase 2 clinical data on TLR7/8 inhibition as a mechanism in moderate-to-severe SLE, a condition for which additional targeted therapies are being explored. The numerically improved BICLA rates across all doses suggest some potential biological activity, but the failure to establish a dose-response relationship means the study cannot identify an optimal therapeutic dose or confirm that the observed improvements are dose-driven. These findings will require careful consideration before advancing enpatoran into later-phase development for SLE.
How to Read This Result
Although the trial was rigorously designed and conducted at scale, the primary endpoint was not met, and the unexplained non-linear dose-response pattern — combined with confidence intervals that overlap with no effect at the two higher doses — means considerable uncertainty remains about whether and at what dose enpatoran provides meaningful clinical benefit in SLE.
Limitations
The primary objective of demonstrating a statistically significant dose-dependent effect on BICLA response was not achieved (p=0.14), which fundamentally limits the conclusions that can be drawn about dosing. The basket trial design, which used different randomisation ratios in Part 1 and Part 2, introduces analytical complexity that may affect the interpretation of dose-group comparisons. The mandated glucocorticoid taper protocol, while clinically relevant, represents an additional variable that could have independently influenced response rates and obscured or modified any true dose-response signal. Finally, the finding that the lowest dose (25 mg) produced the numerically strongest effect — running counter to conventional dose-response assumptions — remains biologically unexplained and warrants further investigation.